RecruitingPhase 2NCT06300320

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

52 participants

Start Date

May 7, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Graft Versus Host Disease

Summary

This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TQ05105 tablets for people with chronic graft versus host disease. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQ05105 tablets

Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.

Locations(12)

Anhui Provincial Hospital

Hefei, Anhui, China

The 940th hospital of joint logistics support force of Chinese people's liberation army

Lanzhou, Gansu, China

Guangzhou First People's Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Tai'an Central Hospital

Taian, Shangdong, China

Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shannxi, China

Hematology Hospital of the Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

The Affiliated People's Hospital of Ningbo University

Ningbo, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06300320

Related Trials

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT059227616 locations

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT059966275 locations

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT0711603133 locations

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT0712407841 locations